This Issue: and lots more… MAPS-affiliated researchers published their second Phase 3 study of MDMA-assisted therapy (MDMA-AT) for PTSD last week.The data looks remarkably similar to that produced by the first Phase 3, MAPP1. This paves the way for a New Drug Application submission, which is expected to happen in the coming months. If all goes to plan, we could see an approval next year.Read more…


Previous articleNuminus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine
Next articlePT443 – Swimming in the Sacred: The Wisdom of Underground Female Elders